抗磷脂酶A2受体抗体在原发性膜性肾病患者中的研究进展

doi:10.3969/j.issn.1004-583X.2021.06.019

摘要/Abstract

摘要：

膜性肾病是成人肾病综合征的常见病因之一,大约75%的膜性肾病为原发性,其他病因包括自身免疫性疾病、感染、药物和恶性肿瘤等。血清抗磷脂酶A2受体(PLA2R)抗体被认为是原发性膜性肾病的血清学诊断的生物标记物,并且该抗体与原发性膜性肾病的诊断、疾病活动、治疗效果、病情评估等密切相关,但国内外研究显示PMN中抗PLA2R抗体阳性率存在差异,以及特异性方面存在疑惑,值得进一步探讨。本文就抗PLA2R抗体与PMN的研究进展作一综述。

关键词: 肾小球肾炎, 膜性, 受体, 磷脂酶A2, 诊断, 鉴别

中图分类号:

R692.31

刘一坤, 刘冰, 冯珍. 抗磷脂酶A2受体抗体在原发性膜性肾病患者中的研究进展[J]. 临床荟萃, 2021, 36(6): 569-573.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.06.019

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I6/569

参考文献 38

[1]	张明超, 经艳, 郑男君, 等. 肾组织PLA2R抗原检测方法的建立和评估[J]. 中华肾脏病杂志, 2018, 34(5):385-386.
[2]	Ronco P, Debiec H. Anti-phospho1ipase A2 receptor antibodies and the pathogenesis of membranous nephropathy[J]. Nephron Clin Pract, 2014, 128(3/4):232-237. doi: 10.1159/000368588 URL
[3]	Beck LH, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J]. N Engl J Med, 2009, 361(1):11-21. doi: 10.1056/NEJMoa0810457 URL
[4]	方玲, 顾向明, 周泽红, 等. 两种方法检测血清抗磷脂酶A2受体抗体在膜性肾病中的应用分析[J]. 检验医学与临床, 2017, 14(15):2196-2198.
[5]	Corrado M, Maurizio B, Giovanni C, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy[J]. Clin J Am Soc Nephrol, 2012, 7(9):1-7. doi: 10.2215/CJN.12121111 URL
[6]	Zhang D, Zou J, Zhang C, et al. Clinical and histological features of phospholipase A2 receptor-associated and thrombospondin type-I domain-containing 7A-associated idiopathic membranous nephropathy: A single center retrospective study from China[J]. Med Sci Monit, 2018, 24(1):5076-5083. doi: 10.12659/MSM.909815 URL
[7]	Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy[J]. Clin J Am Soc Nephrol, 2017, 12(10):1-10. doi: 10.2215/CJN.11511116 URL
[8]	Vincenzo LI, Federico P, Alberto SR, et al. Routine immunohistochemical staining in membranous nephropathy: In situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain[J]. J Nephrol, 2018, 31(4):543-550. doi: 10.1007/s40620-018-0489-z URL
[9]	王述莲, 孙钧, 郑继伟, 等. 抗磷脂酶A2受体抗体表达在特发性膜性肾病人肾组织及血液中的检测价值[J]. 实用医学杂志, 2016, 32(3):434-436.
[10]	詹富国, 吴秀风, 许文燊, 等. 血清抗磷脂酶A2受体抗体在特发性膜性肾病中的诊断价值[J]. 中国卫生标准管理, 2017, 8(18):110-111.
[11]	Radice A, Pieruzzi F, Trezzi B, et al. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases[J]. J Nephrol, 2018, 31(2):271-278. doi: 10.1007/s40620-017-0451-5 pmid: 29081027
[12]	Garcia-Vives E, Solé C, Moliné T, et al. Antibodies to M-type phospholipase A2 receptor (PLA2R) in membranous lupus nephritis[J]. Lupus, 2019, 28(3):1-10.
[13]	许向青, 朱雪婧, 袁曙光, 等. M型磷脂酶A2受体及其抗体在乙肝病毒相关性膜性肾病中的临床意义[J]. 中南大学学报(医学版), 2016, 41(10):1064-1068.
[14]	Tian C, Li L, Liu T, et al. Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy[J]. Int Urol Nephrol, 2019, 51(8):1371-1377. doi: 10.1007/s11255-019-02146-w URL
[15]	蒋真斌, 蔡美顺, 董葆, 等. 适合中国人的抗磷脂酶A2受体抗体临界值的界定[J]. 中华肾脏病杂志, 2020, 36(5):379-384.
[16]	计蕾, 余慰, 钟雪. 特发性膜性肾病患者血清抗磷脂酶A2受体抗体与尿中IgG4检测的临床意义[J]. 中国免疫学杂志, 2018, 34(7):1050-1053+1058.
[17]	Huang B, Zhang Y, Wang L, et al. Phospholipase A2 receptor antibody IgG4 subclass improves sensitivity and specificity in the diagnosis of idiopathic membranous nephropathy[J]. Kidney Blood Press Res, 2019, 44(4):1-10. doi: 10.1159/000497806 URL
[18]	Wang Y, He YX, Diao TT, et al. Urine anti-PLA2R antibody is a novel biomarker of idiopathic membranous nephropathy[J]. Oncotarget, 2018, 9(1):67-74. doi: 10.18632/oncotarget.19859 pmid: 29416596
[19]	詹富国, 吴秀风, 陈惠娟, 等. 三种实验室指标在膜性肾病中的诊断价值[J]. 中国卫生标准管理, 2017, 8(19):124-126.
[20]	Pang L, Zhang AM, Li HX, et al. Serum anti-PLA2R antibody and glomerular PLA2R deposition in Chinese patients with membranous nephropathy: A cross-sectional study[J]. Medicine, 2017, 96(24):1-7.
[21]	Li C, Li H, Wen YB, et al. Analysis of predictive factors for immunosuppressive response in antiphospholipase A2 receptor antibody positive membranous nephropathy[J]. BMC Nephrol, 2018, 19(1):1-6. doi: 10.1186/s12882-017-0808-y URL
[22]	林伟锋, 李航, 李雪梅, 等. 抗磷脂酶A2受体抗体与特发性膜性肾病的关系[J]. 中华内科杂志, 2015, 54(9):783-788.
[23]	Han WW, Tang LJ, Kong XL, et al. Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy[J]. Exp Ther Med, 2019, 17(3):1825-1830.
[24]	Zhang Q, Huang B, Liu X, et al. Ultrasensitive quantitation of anti-phospholipase A2 receptor antibody as a diagnostic and prognostic indicator of idiopathic membranous nephropathy[J]. Sci Rep, 2017, 7(1):12049. doi: 10.1038/s41598-017-12014-1 URL
[25]	Wu X, Liu L, Guo Y, et al. Clinical value of a serum anti-PLA2R antibody in the diagnosis and monitoring of primary membranous nephropathy in adults[J]. Int J Nephrol Renovasc Dis, 2018, 11:241-247. doi: 10.2147/IJNRD URL
[26]	Kim YG, Choi YW, Kim SY, et al. Anti-phospholipase A2 receptor antibody as prognostic indicator in idiopathic membranous nephropathy[J]. Am J Nephrol, 2015, 42(3):250-257. doi: 10.1159/000440983 URL
[27]	褚晓鑫, 徐秀, 何晓峰, 等. 血清抗磷脂酶A2受体抗体在特发性膜性肾病缓解中的价值[J]. 2018(10):752-758.
[28]	Provatopoulou S, Kalavrizioti D, Stangou M, et al. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study[J]. Rom J Intern Med, 2018, 57(2):141-150.
[29]	Guo N, Cao Y, Dai H, et al. Anti-phospholipase A2 receptor (Anti-PLA2R) antibody in diagnosis and treatment of idiopathic membranous nephropathy: A single-center observational study in China[J]. Med Sci Monit, 2019, 25:9364-9368. doi: 10.12659/MSM.917732 URL
[30]	Pourcine F, Dahan K, Mihout F, et al. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years[J]. PLoS One, 2017, 12(3):e0173201. doi: 10.1371/journal.pone.0173201 URL
[31]	Jung OY, Hee YS, Ki KD, et al. Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy[J]. PLoS One, 2013, 8(4):e62151. doi: 10.1371/journal.pone.0062151 URL
[32]	Dong D, Fan TT, Wang YY, et al. Relationship between renal tissues phospholipase A2 receptor and its serum antibody and clinical condition and prognosis of idiopathic membranous nephropathy: a meta-analysis[J]. BMC Nephrol, 2019, 20(1):444. doi: 10.1186/s12882-019-1638-x pmid: 31791262
[33]	Liang Y, Wan J, Chen Y, et al. Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: A meta-analysis[J]. BMC Nephrol, 2019, 20(1):360. doi: 10.1186/s12882-019-1544-2 URL
[34]	Qu Z, Zhang MF, Cui Z, et al. Antibodies against M-type phospholipase A2 receptor may predict treatment response and outcome in membranous nephropathy[J]. Am J Nephrol, 2018, 48(6):1-9. doi: 10.1159/000490625 URL
[35]	Joo SE, Hwa JK, Ae YY, et al. Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy[J]. Kidney Res Clin Pract, 2018, 37(3):248-256. doi: 10.23876/j.krcp.2018.37.3.248 URL
[36]	Hirotaka M, Ken Y, Hirofumi N, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes[J]. Ann Rheum Dis, 2009, 75(4):652-659.
[37]	侯俊英. 抗PLA2R抗体对特发性膜性肾病患者终末期肾病的预测价值[J]. 中国中西医结合肾病杂志, 2020, 21(1):63-65.
[38]	Rodas LM, Matas-García A, Barros X, et al. Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy[J]. Clin Kidney J, 2019, 12(1):36-41. doi: 10.1093/ckj/sfy005 pmid: 30747150

抗磷脂酶A2受体抗体在原发性膜性肾病患者中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 38

相关文章 15

编辑推荐

Metrics

本文评价

[1]	游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.
[2]	赵浩天, 李丽. 肺超声在心脏急重症疾病合并肺水肿中应用的研究进展[J]. 临床荟萃, 2023, 38(9): 832-837.
[3]	陈聪水, 李园, 陈淑芳. 重视儿童胆源性胰腺炎的中西医诊治(附1例分析)[J]. 临床荟萃, 2023, 38(8): 726-730.
[4]	王涛, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗磷脂酶A2受体抗体与特发性膜性肾病的相关性[J]. 临床荟萃, 2023, 38(7): 606-612.
[5]	陈瑾, 吕鸿雁, 刘晗, 刘建宁, 卢佳配, 张金巧. 靶向BCMA的嵌合抗原受体T细胞治疗三重难治性多发性骨髓瘤的研究进展[J]. 临床荟萃, 2023, 38(7): 654-658.
[6]	裴红运, 文洁, 山凤莲. 结核病患者淋巴细胞程序性细胞死亡受体-1表达变化的研究进展[J]. 临床荟萃, 2023, 38(7): 659-662.
[7]	高秦宇, 包蓓艳, 金燕, 赵宇. IgA肾病合并抑郁状态患者的临床特征和预后影响因素分析[J]. 临床荟萃, 2023, 38(6): 510-515.
[8]	沃拉孜汗·玛德尼亚提, 迪力夏提·图尔迪麦麦提, 李梦晨, 拜合提尼沙·吐尔地. 宏基因组二代测序技术在肺结核诊断中应用价值的meta分析[J]. 临床荟萃, 2023, 38(5): 389-398.
[9]	李蕾, 赵永超, 郑加香. 儿童Graves病的诊治新进展[J]. 临床荟萃, 2023, 38(5): 477-480.
[10]	黎恒楠, 黄艳, 赵亚娟, 胡桂才. 血清CTRP5与持续非卧床腹膜透析患者左室舒张功能异常的相关性及其诊断价值[J]. 临床荟萃, 2023, 38(4): 324-329.
[11]	柴春艳, 王婷. 老年高钙血症3例并文献复习[J]. 临床荟萃, 2023, 38(2): 166-169.
[12]	郭雨, 李永东. ARNI在高血压治疗中的研究进展[J]. 临床荟萃, 2023, 38(2): 181-184.
[13]	陶嘉楠, 李文茜, 马秀雯, 安琪, 王学红. HER-2在肝细胞癌中表达及临床意义的meta分析[J]. 临床荟萃, 2023, 38(12): 1067-1072.
[14]	王军宏, 高振华, 章荣龙, 姬浩民, 赵信科, 达明绪. 1980-2021年胃癌诊断文献相关质量分析——基于Web of Science 数据库的文献计量学分析[J]. 临床荟萃, 2023, 38(12): 1117-1124.
[15]	李仁霞, 周泽平. 血小板生成素受体激动剂在成人免疫性血小板减少症中的应用[J]. 临床荟萃, 2023, 38(12): 1140-1145.